Never mind the .  for quality control problems. Sales of prescription drugs to the U.S. by the Indian pharmaceutical industry likely won’t take a huge hit, at least according to a new report.. Why? India’s generic drug makers remain large suppliers to American consumers, writes India Research & Ratings. The FDA may have banned imports from 21 Indian manufacturing plants last year – more than in any other year – but Indian drug makers accounted for 40 percent of U.S. generic drug imports, based on volume, and 39 percent of total generic drug approvals by the agency.. Moreover, the ratings firm believes that the Affordable Care Act will further expand the U.S. market for lower-cost generics. Already, 86% of prescriptions filled in the U.S. last year were for generics, according to the IMS Institute for Healthcare Informatics. And so, the firm forecasts the Indian pharmaceutical industry should experience compounded annual growth of 20% for the next five years. More on this after the jump…